Carboplatin News and Research

RSS

Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers).

High-throughput screening identifies potential drugs for low-grade serous ovarian cancer

In a recent study, researchers used high-throughput drug screening to identify potential therapeutic targets and novel treatments for low-grade serous ovarian cancer (LGSOC), offering hope for more effective and personalized therapies.

26 Sep 2024

RYBREVANT Receives EC Nod for Advanced Lung Cancer Treatment

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved a Type II extension of indication for RYBREVANT®▼ (amivantamab) in combination with chemotherapy (carboplatin and pemetrexed), for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (ex19del) or Exon 21 L858R substitution (L858R) mutations, after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).

30 Aug 2024

ReSisTrace: Unveiling Pre-Existing Treatment Resistance in Cancer Cells

In many cancers, such as ovarian cancer, each round of chemotherapy kills the majority of cancer cells, while a small population of them survives through treatment.

14 Feb 2024

Targeting eIF4A with Zotatifin: A Promising Strategy for TNBC Treatment

Enhancing treatment options for triple-negative breast cancer (TNBC), a highly aggressive tumor with a grim prognosis and limited therapeutic possibilities has proven to be a formidable challenge.

31 Oct 2023

Single-cell spatial analysis may provide information about neoadjuvant therapy for triple-negative breast cancer

A next-generation technology that allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment (TME) was feasible and provided information on the benefit of adding the immune checkpoint inhibitor atezolizumab (Tecentriq) to chemotherapy as neoadjuvant treatment for patients with early high-risk and locally advanced triple negative breast cancer (TNBC), according to results presented at the San Antonio Breast Cancer Symposium, held December 7-10, 2021.

8 Dec 2021

New approach to identify molecular targets for improved prostate cancer therapy

In a new study, researchers have introduced DSER, a technique for identifying molecular targets for enhanced therapy in prostate cancer.

14 Sep 2021

Scientists find gene signature linked to worst prognosis in rare uterine cancer

Women who don't survive a rare and aggressive uterine cancer called uterine serous carcinoma, have high expression of a group of 73 genes, a score scientists say can help identify these women and improve their outcome.

22 Apr 2020